Clinicopathological and molecular landscape of 5-year IDH-wild-type glioblastoma survivors: A multicentric retrospective study

Cancer Lett. 2024 Apr 28:588:216711. doi: 10.1016/j.canlet.2024.216711. Epub 2024 Feb 27.

Abstract

Five-year glioblastoma (GBM) survivors (LTS) are the minority of the isocitrate dehydrogenase (IDH)-wild-type GBM patients, and their molecular fingerprint is still largely unexplored. This multicenter retrospective study analyzed a large LTS-GBM cohort from nine Italian institutions and molecularly characterized a subgroup of patients by mutation, DNA methylation (DNAm) and copy number variation (CNV) profiling, comparing it to standard survival GBM. Mutation scan allowed the identification of pathogenic variants in most cases, showing a similar mutational spectrum in both groups, and highlighted TP53 as the most commonly mutated gene in the LTS group. We confirmed DNAm as a valuable tool for GBM classification with a diagnostic refinement by using brain tumor classifier v12.5. LTS were more heterogeneous with more cases classified as diffuse pediatric high-grade glioma subtypes and having peculiar CNVs. We observed a global higher methylation in CpG islands and in gene promoters of LTS with methylation levels of distinct gene promoters correlating with prognosis.

Keywords: Copy number variation; DNA methylation; IGFBP3; Long term survival glioblastoma; Mutation profile.

Publication types

  • Multicenter Study

MeSH terms

  • Brain Neoplasms* / pathology
  • Child
  • DNA Copy Number Variations
  • DNA Methylation
  • Glioblastoma* / pathology
  • Humans
  • Isocitrate Dehydrogenase / genetics
  • Mutation
  • Prognosis
  • Retrospective Studies
  • Survivors

Substances

  • Isocitrate Dehydrogenase